Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extrapulmonary small cell carcinoma

E Galanis1, S Frytak, R V Lloyd

  • 1Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

Cancer
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

Neuro-oncology·2025
Same author

The use of multiple hypothesis-generating methods in an outbreak investigation of <i>Escherichia coli</i> O121 infections associated with wheat flour, Canada 2016-2017.

Epidemiology and infection·2020
Same author

Online population control surveys: A new method for investigating foodborne outbreaks.

Epidemiology and infection·2020
Same author

Establishing criteria to initiate enteric outbreak investigations in British Columbia.

Canada communicable disease report = Releve des maladies transmissibles au Canada·2020
Same author

Shiga toxin-producing <i>Escherichia coli</i> in British Columbia, 2011-2017: Analysis to inform exclusion guidelines.

Canada communicable disease report = Releve des maladies transmissibles au Canada·2019
Same author

Outbreak of <i>Salmonella</i> Chailey infections linked to precut coconut pieces - United States and Canada, 2017<sup>†</sup>.

Canada communicable disease report = Releve des maladies transmissibles au Canada·2019
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Extrapulmonary small cell carcinoma (EPSCCA) is a rare and often fatal cancer. While surgery can be curative for early-stage disease, most patients have poor outcomes, highlighting the need for multimodal treatment strategies.

Area of Science:

  • Oncology
  • Pathology

Background:

  • Extrapulmonary small cell carcinoma (EPSCCA) is a distinct and often underrecognized entity separate from small cell lung carcinoma.
  • This study reviews institutional experience with EPSCCA, focusing on epidemiology and treatment response.

Purpose of the Study:

  • To analyze the clinical characteristics and treatment outcomes of extrapulmonary small cell carcinoma.
  • To emphasize the epidemiology and response to treatment for these rare neoplasms.

Main Methods:

  • Retrospective review of EPSCCA patient records from 1974-1994.
  • Inclusion criteria required normal chest imaging and negative cytology/bronchoscopy, excluding well-differentiated neuroendocrine and Merkel cell carcinomas.

Main Results:

Related Experiment Videos

  • Gastrointestinal tract was the most common primary site (29 patients).
  • For limited disease (54 patients), surgery offered a 3-year disease-free survival of 25%, while chemotherapy/radiation yielded 83% relapse rate.
  • Platinum-based chemotherapy showed a 72% response rate in extensive/recurrent disease, with a median duration of 8.5 months.

    • Conclusions:

    • EPSCCA has a poor prognosis, with a 13% 5-year survival rate.
    • Surgery may be curative for localized tumors; adjuvant chemotherapy should be considered.
    • Combined chemotherapy and radiation may be as effective as surgery for limited disease, though responses are often transient.